Analysts Offer Predictions for Kura Oncology FY2025 Earnings

Kura Oncology, Inc. (NASDAQ:KURA) – Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of Kura Oncology in a report released on Tuesday, March 4th. Cantor Fitzgerald analyst L. Watsek anticipates that the company will post earnings per share of ($2.94) for the year. Cantor Fitzgerald has a “Strong-Buy” rating on the stock. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share.

Other research analysts have also issued reports about the stock. Bank of America reduced their target price on shares of Kura Oncology from $36.00 to $29.00 and set a “buy” rating on the stock in a report on Friday, November 22nd. Jefferies Financial Group dropped their target price on Kura Oncology from $32.00 to $28.00 and set a “buy” rating on the stock in a report on Thursday, November 21st. TD Cowen reissued a “buy” rating on shares of Kura Oncology in a report on Thursday, November 21st. JMP Securities reissued a “market outperform” rating and issued a $28.00 price objective on shares of Kura Oncology in a report on Thursday, February 6th. Finally, HC Wainwright reiterated a “buy” rating and set a $40.00 price objective on shares of Kura Oncology in a research note on Thursday, February 27th. Four research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $27.13.

Kura Oncology Trading Up 0.5 %

NASDAQ:KURA opened at $7.37 on Thursday. The company has a market capitalization of $573.12 million, a PE ratio of -3.12 and a beta of 0.85. Kura Oncology has a 52-week low of $6.98 and a 52-week high of $24.17. The stock’s 50 day moving average price is $8.07 and its 200 day moving average price is $13.56. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.43. The business had revenue of $53.88 million during the quarter, compared to analyst estimates of $57.96 million.

Institutional Trading of Kura Oncology

Hedge funds have recently made changes to their positions in the stock. Harbor Capital Advisors Inc. grew its stake in shares of Kura Oncology by 21.9% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 47,295 shares of the company’s stock valued at $924,000 after purchasing an additional 8,505 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its stake in Kura Oncology by 35.2% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 29,655 shares of the company’s stock worth $579,000 after acquiring an additional 7,722 shares in the last quarter. Intech Investment Management LLC bought a new position in Kura Oncology in the third quarter worth approximately $298,000. Charles Schwab Investment Management Inc. boosted its holdings in shares of Kura Oncology by 2.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 624,952 shares of the company’s stock valued at $12,212,000 after buying an additional 14,106 shares in the last quarter. Finally, Algert Global LLC increased its position in Kura Oncology by 4.4% during the 3rd quarter. Algert Global LLC now owns 272,276 shares of the company’s stock valued at $5,320,000 after buying an additional 11,493 shares in the last quarter.

Insiders Place Their Bets

In related news, insider Mollie Leoni sold 4,963 shares of Kura Oncology stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the transaction, the insider now directly owns 88,253 shares in the company, valued at approximately $694,551.11. The trade was a 5.32 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Thomas James Doyle sold 4,949 shares of the stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the sale, the senior vice president now owns 88,193 shares in the company, valued at $694,078.91. This trade represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 11,729 shares of company stock worth $92,307. Corporate insiders own 5.50% of the company’s stock.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.